A new generation of antithrombotic agents has recently emerged. These provide direct
inhibition of either thrombin (factor IIa [FIIa]) or FXa, and are increasingly replacing the …

Bleeding is the most common complication of all anticoagulants. Any bleeding patient on an
anticoagulant should be risk-stratified based on hemodynamic instability, source of …

Background In clinical practice, physicians are given the choice of selecting one of two
dabigatran doses based on patient characteristics, with the lower dose typically used in …

Pancreatitis, the inflammatory disorder of the pancreas, has no specific therapy. Genetic,
biochemical, and animal model studies revealed that trypsin plays a central role in the onset …

Background Patients with atrial fibrillation (AF) who are on long-term direct oral
anticoagulants (DOAC) with low anti-Xa or anti-IIa levels may be at higher risk of recurrent …

Anticoagulant drugs have been used to prevent and treat thrombosis. However, they are
associated with risk of hemorrhage. Therefore, prior to their clinical use, it is important to …

Essentials• Anticoagulants need to be stopped preprocedure so there is little or no
remaining anticoagulant effect.• We assessed the residual anticoagulant effect with …

Thrombin acts as a key enzyme in the blood coagulation cascade and represents a potential
drug target for the treatment of several cardiovascular diseases. The aim of this study was to …

Patients with atrial fibrillation (AF) on long-term direct oral anticoagulants (DOACs) may be
at higher risk of bleeding because of higher anti-Xa or anti-IIa levels. However, there is no …

Direct oral anticoagulants (DOACs) are increasingly used worldwide for the prevention of
stroke in patients with atrial fibrillation and to prevent or treat venous thromboembolism. In …